8-K - PMGC Holdings Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

PMGC Holdings Inc.'s subsidiary, Northstrive Biosciences Inc., entered into a Third Amendment to its License Agreement with MOA Life Plus Co., Ltd. on March 24, 2026, which updates development milestones and timelines for the human health field and requires a one-time payment to MOA.

Key Takeaways

1Northstrive Biosciences Inc., a wholly owned subsidiary of PMGC Holdings Inc., entered into a Third Amendment to its License Agreement with MOA Life Plus Co., Ltd.

2The Third Amendment's effective date is March 24, 2026.

3The amendment amends and restates Exhibit C of the License Agreement, updating development milestones and timelines for the human health field.

4The updated milestones include initiation of pre-clinical IND-enabling study, submission of an IND to the FDA, and initiation of Phase 1, Phase 2, and Phase 3 clinical trials.

5PMGC Holdings Inc. must pay MOA a one-time, non-creditable, non-refundable amendment fee within 30 days after the Third Amendment Effective Date.

6For the licensed product BLS-M22, Northstrive may be excused from initiating a Phase 1 clinical trial if it provides acceptable documentation and proceeds directly to Phase 2.

Current Report Details

Event Type

Material Agreement

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. Third Amendment to License Agreement between Northstrive Biosciences Inc. and MOA Life Plus Co., Ltd. As of March 24

Material Agreement

Source Document

9.01

. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Third Amendment to License Agreement between Northstrive Biosciences Inc. and MO

Exhibits Only

Transaction Details

Material Agreement

Agreement: Third Amendment to License Agreement
Parties: Northstrive Biosciences Inc., MOA Life Plus Co., Ltd.

•Amends and restates Exhibit C (Development Milestones) of the License Agreement
•Updates milestones and timelines for the human health field
•Requires PMGC to pay MOA a one-time amendment fee within 30 days after the Third Amendment Effective Date
•Provides for potential waiver of Phase 1 clinical trial milestone for product BLS-M22 under specified conditions

Exhibits (2)

10.1

THIRD AMENDMENT TO LICENSE AGREEMENT BETWEEN NORTHSTRIVE BIOSCIENCES INC. AND MOA LIFE PLUS CO., LTD

8-K

CURRENT REPORT